Daunorubicin

Research summary

Research on daunorubicin is extensive but almost entirely focused on cancer patients, especially those with acute myeloid leukemia, where it remains a backbone of induction chemotherapy regimens. Numerous clinical trials and cohort studies compare different daunorubicin doses, schedules, and combinations with other chemotherapeutic agents or adjunctive drugs to optimize remission rates and survival while managing toxicity. There are essentially no studies investigating daunorubicin for health enhancement in healthy volunteers. When healthy or non-cancer participants are included, it is typically for pharmacokinetic, safety, or interaction-focused evaluations rather than for any wellness or performance benefits. The overall research consensus is that daunorubicin is a powerful anticancer agent with substantial toxicity, appropriate only for carefully selected patients with malignancy and not suitable for any supplemental use in healthy adults.